DESTINY-Breast09 (Exploratory CNS Analysis)
#ESMO26

T-DXd + P demonstrated superior efficacy versus THP in HER2+ metastatic breast cancer with brain metastases (n=61).

Systemic PFS: HR 0.30
CNS-PFS: HR 0.26
CNS-ORR: 51.6% vs 26.7%
Systemic ORR: 83.9% vs 70.0%

Supports T-DXd + P as first-line therapy, including patients with brain metastases.